Cancers & treatments·Comprehensive genomic profiling·Exome and genome sequencing

Tumour sequencing tests

24 tests from 13 laboratories side by side: whether they need tissue or blood, whether they read a chosen panel of genes, the whole exome, the exome plus the RNA, or only trace tumour DNA after treatment, what the report contains, and the regulatory status where it is certain. A blank cell means OnCo does not state it.

How to read this

Most tests here are laboratory-developed tests: run in one accredited laboratory in the United States under CLIA rules rather than approved as a kit. FDA approval applies to a specific version with named companion diagnostic claims, and CE marking to sale in Europe. Which test you get depends on your hospital, your country and your insurer; in England the NHS Genomic Medicine Service funds the tests in its directory. Ask the treating team which test was run and for the report itself; the report reader explains the values.

By scope

Exome plus transcriptomeReads the coding DNA and the RNA, so it also sees which genes are switched on and catches fusions.BostonGene Tumor Portrait Caris MI Profile Caris MI Cancer Seek Exact Sciences OncoExTra
ExomeReads the protein-coding part of every gene, about one to two per cent of the genome.Tempus xE Natera Altera
Targeted panelReads a chosen set of cancer genes, usually a few hundred, at high depth.Tempus xT and xT CDx FoundationOne CDx FoundationOne Liquid CDx FoundationOne Heme Guardant360 CDx StrataNGS StrataEXP NeoGenomics NeoTYPE profiles Illumina TruSight Oncology 500 Illumina TruSight Oncology Comprehensive Myriad myChoice CDx Exact Sciences Oncotype DX Breast Recurrence Score Labcorp OmniSeq INSIGHT
MRD (residual disease)Looks in blood for traces of tumour DNA after treatment, to catch relapse early.Guardant Reveal NeoGenomics RaDaR Personalis NeXT Personal Natera Signatera
ScreeningLooks in blood for signs of a cancer in someone without symptoms.Guardant Shield

Test	Company	Sample	Scope	What it returns	US status	EU status	Technologies
BostonGene Tumor Portrait The immune microenvironment classification is the distinctive part: it groups tumours by how immune cells are arranged, which BostonGene reports alongside the genomics.	BostonGene	Tissue	Exome plus transcriptome	Somatic mutations, copy number and fusions from whole exome sequencing of tumour and normal, gene expression from RNA sequencing, tumour mutational burden, microsatellite status, and a classification of the tumour's immune microenvironment.	Laboratory-developed test (CLIA laboratory)		Whole-exome & whole-genome sequencing Comprehensive genomic profiling
Caris MI Cancer Seek OnCo record	Caris Life Sciences	Tissue	Exome plus transcriptome	The FDA-approved whole exome and whole transcriptome assay, with companion diagnostic claims for specific drug and cancer pairs alongside the broader profile.	FDA approved (2024)		Whole-exome & whole-genome sequencing Companion diagnostics
Caris MI Profile	Caris Life Sciences	Tissue	Exome plus transcriptome	Whole exome and whole transcriptome sequencing of the tumour, with immunohistochemistry where relevant, reporting mutations, copy number, fusions, expression, tumour mutational burden, microsatellite status and loss of heterozygosity, matched to approved drugs and trials.	Laboratory-developed test (CLIA laboratory); the FDA-approved version is MI Cancer Seek		Whole-exome & whole-genome sequencing Comprehensive genomic profiling RNA sequencing & expression profiling
Exact Sciences OncoExTra	Exact Sciences (Abbott)	Tissue	Exome plus transcriptome	Whole exome and whole transcriptome sequencing of tumour with matched normal, reporting mutations, copy number, fusions, expression, tumour mutational burden and microsatellite status.	Laboratory-developed test (CLIA laboratory)		Whole-exome & whole-genome sequencing Comprehensive genomic profiling RNA sequencing & expression profiling
Natera Altera	Natera	Tissue	Exome	Whole exome sequencing of the tumour reporting mutations, copy number and fusions, tumour mutational burden and microsatellite status, matched to therapies and trials; the same exome data seeds a Signatera panel.	Laboratory-developed test (CLIA laboratory)		Whole-exome & whole-genome sequencing Comprehensive genomic profiling
Tempus xE	Tempus AI	Tissue	Exome	Whole exome sequencing of tumour and matched normal, reporting somatic and germline variants across the coding genome, tumour mutational burden and microsatellite status.	Laboratory-developed test (CLIA laboratory)		Whole-exome & whole-genome sequencing
Exact Sciences Oncotype DX Breast Recurrence Score OnCo record Not a mutation test: it measures expression of 21 genes to predict recurrence risk and chemotherapy benefit.	Exact Sciences (Abbott)	Tissue	Targeted panel	A 21-gene expression Recurrence Score from 0 to 100 for early hormone receptor positive, HER2 negative breast cancer, estimating the benefit of adding chemotherapy to endocrine therapy.	Laboratory-developed test (CLIA laboratory)		Gene-expression prognostic assays
FoundationOne CDx OnCo record	Foundation Medicine (Roche)	Tissue	Targeted panel	Substitutions, indels, copy number changes and selected rearrangements in 324 genes, plus tumour mutational burden and microsatellite status, with companion diagnostic claims for a long list of targeted drugs.	FDA approved (PMA P170019, 2017)	CE marked	Comprehensive genomic profiling Companion diagnostics
FoundationOne Heme	Foundation Medicine (Roche)	Tissue or blood	Targeted panel	DNA sequencing of several hundred genes plus RNA sequencing of fusion genes for leukaemias, lymphomas, myeloma and sarcomas, from blood, bone marrow or tissue.	Laboratory-developed test (CLIA laboratory)		Comprehensive genomic profiling
FoundationOne Liquid CDx OnCo record	Foundation Medicine (Roche)	Blood	Targeted panel	Alterations in more than 300 genes from cell-free DNA in a blood draw, including blood tumour mutational burden and microsatellite status, with companion diagnostic claims; a negative result does not rule out the alteration in tissue.	FDA approved (PMA P190032, 2020)	CE marked	Liquid biopsy (ctDNA)Comprehensive genomic profiling Companion diagnostics
Guardant360 CDx OnCo record	Guardant Health	Blood	Targeted panel	Mutations, amplifications and fusions in more than 50 genes from cell-free DNA, with companion diagnostic claims in lung and breast cancer; the wider laboratory Guardant360 reports more genes.	FDA approved (PMA P200010, 2020)		Liquid biopsy (ctDNA)Comprehensive genomic profiling Companion diagnostics
Illumina TruSight Oncology 500	Illumina	Tissue or blood	Targeted panel	A kit laboratories run themselves: DNA variants in 523 genes and RNA fusions in 55 genes, plus tumour mutational burden and microsatellite status; a cell-free DNA version exists for blood.	Research use only kit; the in vitro diagnostic version is TruSight Oncology Comprehensive		Comprehensive genomic profiling
Illumina TruSight Oncology Comprehensive OnCo record	Illumina	Tissue	Targeted panel	The in vitro diagnostic form of the TSO 500 content, reporting variants across the same gene set with companion diagnostic claims for fusion-directed drugs.	FDA approved (2024)	CE marked	Comprehensive genomic profiling Companion diagnostics
Labcorp OmniSeq INSIGHT	Labcorp	Tissue	Targeted panel	DNA and RNA sequencing across several hundred genes plus immune gene expression, reporting mutations, fusions, tumour mutational burden, microsatellite status and PD-L1 in one report.	Laboratory-developed test (CLIA laboratory)		Comprehensive genomic profiling Reference laboratories and companion-diagnostic testing
Myriad myChoice CDx OnCo record	Myriad Genetics	Tissue	Targeted panel	BRCA1 and BRCA2 status and a genomic instability score combining loss of heterozygosity, telomeric allelic imbalance and large-scale transitions, reported together as homologous recombination deficiency status.	FDA approved (2019) as a companion diagnostic for PARP inhibitors		Companion diagnostics Comprehensive genomic profiling
NeoGenomics NeoTYPE profiles	NeoGenomics	Tissue or blood	Targeted panel	Cancer-specific DNA and RNA panels (solid tumour, lung, myeloid and others) reporting mutations, copy number and fusions, often combined with immunohistochemistry and FISH from the same laboratory.	Laboratory-developed tests (CLIA laboratory)		Comprehensive genomic profiling Reference laboratories and companion-diagnostic testing
StrataEXP	Strata Oncology	Tissue	Targeted panel	Quantitative gene-expression measurements of drug targets and an immunotherapy response score, meant to be run alongside StrataNGS to inform choice of immunotherapy and antibody-drug conjugates.	Laboratory-developed test (CLIA laboratory)		RNA sequencing & expression profiling Comprehensive genomic profiling
StrataNGS	Strata Oncology	Tissue	Targeted panel	Mutations, copy number, fusions, tumour mutational burden and microsatellite status from a targeted DNA and RNA panel designed to work on very small tissue samples.	Laboratory-developed test (CLIA laboratory)		Comprehensive genomic profiling
Tempus xT and xT CDx OnCo record	Tempus AI	Tissue or blood	Targeted panel	Mutations, copy number and fusions across several hundred genes from tumour tissue with a matched normal sample, plus RNA sequencing for fusions, tumour mutational burden and microsatellite status; xT CDx carries companion diagnostic claims.	xT CDx FDA approved (2023); the laboratory xT assay is a laboratory-developed test		Comprehensive genomic profiling Companion diagnostics
Guardant Reveal OnCo record	Guardant Health	Blood	MRD (residual disease)	Presence or absence of circulating tumour DNA after surgery or during surveillance, using mutations and methylation without needing a tumour sample first, in colorectal, breast and lung cancer.	Laboratory-developed test (CLIA laboratory)		MRD / molecular residual disease testing Liquid biopsy (ctDNA)
Natera Signatera OnCo record	Natera	Blood	MRD (residual disease)	A tumour-informed residual disease result: whole exome sequencing of the tumour and normal picks 16 patient-specific variants, which are then tracked in serial blood samples and reported as detected or not detected with a level.	Laboratory-developed test (CLIA laboratory) with FDA Breakthrough Device designations		MRD / molecular residual disease testing Liquid biopsy (ctDNA)
NeoGenomics RaDaR OnCo record	NeoGenomics	Blood	MRD (residual disease)	A tumour-informed residual disease result: the tumour is sequenced first and a personalised panel of its variants is then tracked in blood over time.	Laboratory-developed test (CLIA laboratory)		MRD / molecular residual disease testing Liquid biopsy (ctDNA)
Personalis NeXT Personal	Personalis (Tempus)	Blood	MRD (residual disease)	An ultra-sensitive tumour-informed residual disease measurement: whole genome sequencing of the tumour designs a panel of up to about 1,800 variants that is then tracked in blood, reported as tumour DNA level over time.	Laboratory-developed test (CLIA laboratory)		MRD / molecular residual disease testing Liquid biopsy (ctDNA)Whole-exome & whole-genome sequencing
Guardant Shield OnCo record	Guardant Health	Blood	Screening	A positive or negative result for colorectal cancer signal in cell-free DNA, for people at average risk aged 45 and over; a positive result leads to colonoscopy.	FDA approved (2024) as a primary colorectal cancer screening option		Liquid biopsy (ctDNA)

Laboratories in this table

BostonGene Caris Life Sciences Exact Sciences (Abbott)Foundation Medicine (Roche)Guardant Health Illumina Labcorp Myriad Genetics Natera NeoGenomics Personalis (Tempus)Strata Oncology Tempus AI

Free routes to testing, including charity-funded sequencing programmes and the NHS directory, are on the free in oncology page. Companion diagnostic assays with FDA claims, by drug, are on the assays page.